Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602219 · ClinicalTrials.gov registry record · Phase 2
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT06602219 is a Phase 2 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 222 participants.
The verdict
NCT06602219, a Phase 2 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG LY4100511
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06602219
The ClinicalTrials.gov registry entry for NCT06602219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06602219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06602219 about?
NCT06602219 is a clinical study titled "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis". The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT06602219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2024-10-25. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT06602219?
The interventions under investigation include: Placebo (DRUG), LY4100511 (DRUG).
Who is sponsoring clinical trial NCT06602219?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.